Hester Biosciences reports 88% Standalone PAT Growth in Q1 FY27; Consolidated Profit Surges on Exceptional Gain
Hester Biosciences reported its Q1 FY27 financial results, posting strong standalone growth while consolidated net profit surged due to an exceptional gain.
What Happened and Why It Matters
Hester Biosciences reported standalone revenue from operations of Rupee 72.66 crore in Q1 FY27, up 14% from Rupee 63.49 crore in the corresponding quarter last year. Standalone profit after tax increased 88% to Rupee 14.71 crore, compared with Rupee 7.84 crore a year earlier.
On a consolidated basis, revenue from operations stood at Rupee 77.24 crore, down 8% year-on-year from Rupee 84.11 crore. However, consolidated profit after tax surged to Rupee 96.73 crore from Rupee 17.30 crore, mainly due to an exceptional gain of Rupee 85.35 crore.
The gain arose after Hester Biosciences Africa Limited amended its loan agreement with the Gates Foundation, reducing the outstanding principal from USD 12 million to USD 5 million, waiving all accrued interest, and converting the revised loan into an interest-free facility.
Business Impact and Strategic Relevance
- Strong Standalone Performance: Revenue rose 14% year-on-year to Rupee 72.66 crore, while profit after tax increased 88% to Rupee 14.71 crore.
- Exceptional Accounting Gain: Consolidated profit was boosted by an exceptional gain of Rupee 85.35 crore following the restructuring of a loan agreement with the Gates Foundation.
- Poultry Healthcare Growth: The division delivered 48% year-on-year revenue growth, supported by higher institutional sales and stronger market penetration.
- Animal Healthcare Remains Under Pressure: Delays in government immunization programmes and tender execution continued to impact the segment's performance.
What to Watch Next
Investors will watch whether Hester Biosciences can sustain growth in its poultry healthcare business while demand in the animal healthcare segment improves as government immunization programmes and tender activity normalize.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Jumbo Bag Reports 145% Jump in Q1 FY27 Profit; Board Approves Preferential Share Allotment
Jumbo Bag Ltd announced its standalone financial results for the first quarter of Q1FY27, reporting growth in revenue and profitability. The company’s board also approved the allotment of 6 lakh equity shares upon the conversion of fully convertible warrants on a preferential basis.
Mangal Electrical Reports 40% Revenue Growth, PAT Doubles In Q1 FY27
Mangal Electrical Industries Ltd. reported strong growth for the quarter ended June 30, 2026 (Q1 FY27), with revenue rising 40% year-on-year and profit after tax more than doubling. The company also announced plans to expand capacity by acquiring land near its Reengus facility and progressing with its transformer manufacturing expansion.
L. T. Elevator Allots 10.80 lakh Shares To Bandhan Small Cap Fund Through a Preferential Issue
L. T. Elevator Limited has completed a preferential allotment of equity shares to Bandhan Small Cap Fund. Following the transaction, the fund has acquired a 5.08% stake in the company, according to a disclosure made under the SEBI (SAST) Regulations.